


# INTERLEUKIN 17A (IL-17A) IN SPONDYLOARTHRITIS (SpA)

IL-17A IS A PROTEIN THAT HAS A KEY ROLE IN THE DEVELOPMENT OF SpA, A FAMILY OF LONG-TERM, DEBILITATING CONDITIONS WHICH CAN AFFECT THE JOINTS AND SPINE. COMMON SpA CONDITIONS ARE PSORIATIC ARTHRITIS (PsA) AND ANKYLOSING SPONDYLITIS (AS).<sup>1,2</sup>

## ROLE OF IL-17A IN SpA<sup>1, 3-7</sup>



## OVERPRODUCTION OF IL-17A CAN AFFECT DIFFERENT PARTS OF THE BODY IN PsA AND AS<sup>2, 8-12</sup>



**Psoriatic arthritis** is a long lasting inflammatory disease associated with significant disability and poor quality of life. People with PsA can have swollen joints and painful tendons, skin and nail psoriasis and swollen toes and fingers. PsA is closely associated with psoriasis.

**Ankylosing spondylitis** is a long lasting inflammatory disease of the joints. It is a progressively debilitating condition caused by inflammation of the spine, pelvis and neck which leads to irreversible damage that significantly reduces patients' mobility and quality of life.

## IL-17A: A POTENTIAL NEW TARGET FOR THE TREATMENT OF SpA

The central role of IL-17A in the development of SpA makes it a promising target for therapeutic intervention for diseases such as PsA and AS.

### References

1. Weaver CT, et al. Annu Rev Immunol. 2007;25:821-52. 2. American College of Rheumatology (ACR) website. Accessed October 2014. 3. Van Baarsen LGM, et al. Ann Rheum Dis. 2011;70:A79. 4. Van Kuijk A and Tak P. Curr Rheumatol Rep. 2011;13(4):353-59. 5. Leipe J, et al. Arthritis Rheum. 2010;62(10):2876-85. 6. Noordenbos T, et al. Arthritis Rheum. 2012;64:99-109. 7. Taylan A, et al. Rheumatol Int. 2012;32:2511-2515. 8. Gladman DD, et al. Ann Rheum Dis. 2005;64:iii14-ii17. 9. Lee Set al. P T. 2010;35(12): 680-689. 10. Sieper J et al. Ann Rheum Dis. 2002;61(Suppl III):iii8-iii18. 11. Lories R. Nat Rev Rheumatol. 2011;7:700-707. 12. Barkham N, et al. Rheum. 2005;44:1277-1281.